Search for novel therapies for triple negative breast cancers (TNBC): Analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH)

Stefan Buchholz, Stephan Seitz, Jörg B. Engel, Alberto Montero, Olaf Ortmann, Roberto Perez, Norman L Block, Andrew V Schally

Research output: Contribution to journalArticle

3 Scopus citations


Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is clinically negative for the expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). Patients with TNBC have a worse clinical outcome, as measured by time to metastasis and median overall survival. Chemotherapy has been the mainstay of treatment of TNBC but responses are disappointing. A substantial proportion of TNBC expresses luteinizing hormone-releasing hormone (LHRH), receptors for LHRH, in addition to receptors for growth hormone-releasing hormone (GHRH). These receptors represent potential therapeutic targets. Potent antagonists of GHRH and LHRH receptors have been developed in recent years and these antagonists inhibit the growth, tumorigenicity and metastatic potential of various human experimental malignancies. These antagonists could be utilized for the treatment of TNBC. The targeted cytotoxic analog of LHRH, AN-152 (AEZS-108) containing doxorubicin, must also be strongly considered for therapy of TNBC. Experimental studies suggest the merit of clinical trials with LHRH antagonists and AEZS-108 in TNBC patients.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalHormone Molecular Biology and Clinical Investigation
Issue number1
StatePublished - Apr 1 2012



  • Antagonists of LHRH
  • GHRH
  • GHRH
  • Receptors for LHRH
  • Targeted cytotoxic analog of LHRH
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)
  • Molecular Biology
  • Endocrinology

Cite this